QUALITY INDICATOR | NUMERATOR | DENOMINATOR | %b CI (95%) | MEDICAL DOCUMENTATION | RATIONALE | |||
---|---|---|---|---|---|---|---|---|
Description | N | Description | N | |||||
QI1 | Proportion of patients with prostate cancer and the diagnosis based on prostatic biopsya. | Number of patients with prostate cancer whose diagnosis was based on prostate biopsya. | 535 | Number of patients with prostate cancer. | 700 of which 683 with available information. | 78.3% (75.2%;81.4%) | Biopsy pathology report. Reports/discharge letters coming from all hospitals units/departments (i.e. surgery, medicine, radiation oncology, medical oncology). | Biopsy is the recognised diagnostic procedure. |
(17 missing: information not retrieved) | ||||||||
QI2 | Proportion of patients with prostate cancer and 8 or more diagnostic prostatic biopsies. | Number of patients with prostate cancer who underwent 8 or more diagnostic prostatic biopsies. | 377 | Number of patients with prostate cancer whose diagnosis was based on prostatic biopsy. | 535 of which 520 with available information. | 72.5% (68.7%;76.3%) | Biopsy pathology report. Request form of pathology examination. | A sufficient number of prostatic biopsies is required for an adequate sampling of the tissue. |
(15 missing: information not retrieved) | ||||||||
QI3 | Proportion of patients with prostate cancer and the pathology report of the biopsy including the following characteristics: - histologic type according to WHO - histologic grade with Gleason score - tumour quantitation (number of positive cores/total number of cores and/or proportion of prostatic tissue involved by tumour). | Number of patients with prostate cancer whose pathology report of the biopsy included the histologic type according to WHO. | 498 | Number of patients with prostate cancer undergoing biopsy. | 535 of which 528 with available information. | 94.3% (92.3%;96.3%) | Biopsy pathology report. | Standardization of microscopic tumour characteristics is necessary for an adequate treatment planning. |
(7 missing: information not retrieved) | ||||||||
Number of patients with prostate cancer whose pathology report of the biopsy included the histologic grade with Gleason score. | 533 | Number of patients with prostate cancer undergoing biopsy. | 535 of which 534 with available information. | 99.8% (99.5%;100.0%) | ||||
(1 missing: information not retrieved) | ||||||||
Number of patients with prostate cancer whose pathology report of the biopsy included tumour quantitation (number of positive cores/total number of cores and/or proportion of prostatic tissue involved by tumour). | 524 | Number of patients with prostate cancer undergoing biopsy. | 535 of which 530 with available information. | 98.9% (98.0%;99.8%) | ||||
(5 missing: information not retrieved) | ||||||||
QI4 | Proportion of patients with prostate cancer and the pathology report of the TUR-P including the following characteristics: - histologic type according to WHO - histologic grade with Gleason score - tumour quantitation (proportion of prostatic tissue involved by tumour). | Number of patients with prostate cancer whose pathology report of the TUR-P included the histologic type according to WHO. | 74 | Number of patients with prostate cancer undergoing TUR-P. | 88 of which 81 with available information. | 91.4% (85.2%;97.5%) | TUR-P pathology report. | Standardization of microscopic tumour characteristics is necessary for an adequate treatment planning. |
(7 missing: information not retrieved) | ||||||||
Number of patients with prostate cancer whose pathology report of the TUR-P included the histologic grade with Gleason score. | 79 | Number of patients with prostate cancer undergoing TUR-P. | 88 of which 84 with available information. | 94.1% (89.0%;99.1%) | ||||
(4 missing: information not retrieved) | ||||||||
Number of patients with prostate cancer whose pathology report of the TUR-P included the tumour quantitation (number of positive cores/total number of cores and/or proportion of prostatic tissue involved by tumour). | 59 | Number of patients with prostate cancer undergoing TUR-P. | 88 of which 81 with available information. | 72.8% (63.1%;82.5%) | ||||
(7 missing: information not retrieved) | ||||||||
QI5 | Proportion of patients with prostate cancer whose pathology report of the prostatectomy with pelvic lymphadenectomy includes the number of resected lymph nodes. | Number of patients with prostate cancer whose pathology report of the prostatectomy with pelvic lymphadenectomy included the number of resected lymph nodes. | 195 | Number of patients with prostate cancer undergoing prostatectomy with pelvic lymphadenectomy. | 197 of which 195 with available information. | 100.0% (100%;100%) | Prostatectomy pathology report. | Standardization of microscopic tumour characteristics is necessary for an adequate treatment planning. |
(2 missing: information not retrieved) | ||||||||
QI6 | Proportion of patients with prostate cancer and the pathology report of the prostatectomy including the following characteristics: - histologic type according to WHO - histologic grade with Gleason score - extraprostatic extension - seminal vescicle invasion - margins status - pathologic staging (pTNM) according to AJCC TNM 7th ed. | Number of patients with prostate cancer whose pathology report of the prostatectomy included the histologic type according to WHO. | 198 | Number of patients with prostate cancer undergoing prostatectomy. | 220 of which 215 with available information. | 92.1% (88.5%;95.7%) | Prostatectomy pathology report. | Standardization of microscopic tumour characteristics is necessary for an adequate treatment planning. |
(5 missing: information not retrieved) | ||||||||
Number of patients with prostate cancer whose pathology report of the prostatectomy included the histologic grade with Gleason score. | 219 | Number of patients with prostate cancer undergoing prostatectomy. | 220 of which 219 with available information. | 100.0% (100%;100%) | ||||
(1 missing: information not retrieved) | ||||||||
Number of patients with prostate cancer whose pathology report of the prostatectomy included the extraprostatic extension. | 198 | Number of patients with prostate cancer undergoing prostatectomy. | 220 of which 215 with available information. | 92.1% (88.5%;95.7%) | ||||
(5 missing: information not retrieved) | ||||||||
Number of patient with prostate cancer whose pathology report of the prostatectomy included the seminal vescicle invasion. | 210 | Number of patients with prostate cancer undergoing prostatectomy. | 220 of which 215 with available information. | 97.7% (95.7%;99.7%) | ||||
(5 missing: information not retrieved) | ||||||||
Number of patients with prostate cancer whose pathology report of the prostatectomy included the margins status. | 216 | Number of patients with prostate cancer undergoing prostatectomy. | 220 of which 220 with available information. | 98.2% (96.4%;100.0%) | ||||
(0 missing: information not retrieved) | ||||||||
Number of patients with prostate cancer whose pathology report of the prostatectomy included the pathologic staging (pTNM) according to AJCC TNM 7th ed. | 219 | Number of patients with prostate cancer undergoing prostatectomy. | 220 of which 220 with available information. | 99.6% (98.7%;100.0%) | ||||
(0 missing: information not retrieved) | ||||||||
QI7 | Proportion of patients with localized (N0, M0) low risk (cT1–2a and Gleason≤6 and PSA ≤ 10 ng/ml) prostate cancer undergoing active surveillance. | Number of patients with localized (N0, M0) low risk (cT1–2a and Gleason≤6 and PSA ≤ 10 ng/ml) prostate cancer who underwent an active surveillance. | 33 | Number of patients with localized (N0, M0) low risk (cT1–2a and Gleason≤6 and PSA ≤ 10 ng/ml) prostate cancer. | 84 of which 71 with available information. | 46.5% (34.9%;58.1%) | Reports/discharge letters coming from all hospitals units/departments (i.e. surgery, medicine, radiation oncology, medical oncology). | Guidelines indicate active surveillance as preferred treatment for low risk prostate cancers. |
(13 missing: information not retrieved) | ||||||||
QI8 | Proportion of patients with localized (N0, M0) high risk (cT3–4 or Gleason≥8 or PSA ≥ 20 ng/ml) prostate cancer undergoing radical treatment (radical prostatectomy ± pelvic lymphadenectomy, RT or brachytherapy). | Number of patients with localized (N0, M0) high risk (cT3–4 or Gleason≥8 or PSA ≥ 20 ng/ml) prostate cancer who underwent a radical treatment (radical prostatectomy ± pelvic lymphadenectomy, RT or brachytherapy). | 144 | Number of patients with localized (N0, M0) high risk (cT3–4 or Gleason≥8 or PSA ≥ 20 ng/ml) prostate cancer. | 248 of which 208 with available information. | 69.2% (63.0%;75.5%) | Reports/discharge letters coming from all hospitals units/departments (i.e. surgery, medicine, radiation oncology, medical oncology). | Guidelines indicate prostatectomy as 1st line treatment for high risk prostate cancers. |
(40 missing: information not retrieved) | ||||||||
QI9 | Proportion of patients with localized (N0, M0) high risk (cT3–4 or Gleason≥8 or PSA ≥ 20 ng/ml) prostate cancer undergoing radical RT with neo-adjuvant HT. | Number of patients with localized (N0, M0) high risk (cT3–4 or Gleason≥8 or PSA ≥ 20 ng/ml) prostate cancer who underwent a neo-adjuvant HT before radical RT. | 66 | Number of patients with localized (N0, M0) high risk (cT3–4 or Gleason≥8 or PSA ≥ 20 ng/ml) prostate cancer undergoing radical RT. | 75 of which 75 with available information. | 88.0% (80.7%;95.4%) | Reports/discharge letters coming from all hospitals units/departments (i.e. surgery, medicine, radiation oncology, medical oncology). | In high risk prostate cancer, treated with RT, the use of neo-adjuvant HT improves overall survival. |
(0 missing: information not retrieved) | ||||||||
QI10 | Proportion of patients with non-metastatic (M0) pT2 or pT3 prostate cancer undergoing prostatectomy ± pelvic lymphadenectomy with uninvolved marginsa. | Number of patients with non-metastatic (M0) pT2 or pT3 prostate cancer who underwent prostatectomy ± pelvic lymphadenectomy with uninvolved margins. | 97 (pT2) 40 (pT3) | Number of patients with non-metastatic (M0) pT2 or pT3 prostate cancer undergoing prostatectomy ± pelvic lymphadenectomy. | 118 (pT2)/97 (pT3) of which 118/97 with available information. | 82.2% (pT2) (75.3%;89.1%) 41.2% (pT3) (31.4%;51.0%) | Prostatectomy pathology report. | Margins status is the only criteria for evaluating the radicality of the prostatectomy. |
(0 missing: information not retrieved) | ||||||||
QI11 | Proportion of patients with non-metastatic (M0) prostate cancer undergoing external beam RT with dose escalation to at least 74 Gy. | Number of patients with non-metastatic (M0) prostate cancer who underwent an external beam RT with dose escalation to at least 74 Gy. | 148 | Number of patients with non-metastatic (M0) prostate cancer undergoing RT. | 198 of which 194 with available information. | 76.3% (70.3%;82.3%) | Reports/discharge letters coming from all hospitals units/departments (i.e. surgery, medicine, radiation oncology, medical oncology). | RT dose escalation between 74 and 78 Gy increases biochemical control of prostate cancer. |
(4 missing: information not retrieved) | ||||||||
QI12 | Proportion of patients with metastatic (M1) prostate cancer undergoing immediate (within 3 months from the diagnosis) HT or bilateral orchiectomy. | Number of patients with metastatic (M1) prostate cancer who underwent HT or bilateral orchiectomy within 3 months from the diagnosis. | 50 | Patients with metastatic (M1) prostate cancer. | 74 of which 68 with available information. | 73.5% (63.0%;84.0%) | Reports/discharge letters coming from all hospitals units/departments (i.e. surgery, medicine, radiation oncology, medical oncology). | HT is the indicated treatment for metastatic prostate cancer. |
(6 missing: information not retrieved) | ||||||||
QI13 | Proportion of patients with non-metastatic (M0) prostate cancer dead within 30 days after prostatectomy ± pelvic lymphadenectomy (post-operative mortality). | Number of patients with non-metastatic (M0) prostate cancer who died within 30 days after prostatectomy ± pelvic lymphadenectomy. | 1 | Number of patients with non-metastatic (M0) prostate cancer undergoing prostatectomy ± pelvic lymphadenectomy. | 219 of which 219 with available information. | 0.5% (0.0%; 1.4%) | Reports/discharge letters coming from all hospitals units/departments (i.e. surgery, medicine, radiation oncology, medical oncology). | Indicator for the outcome after radical prostatectomy. |
(0 missing: information not retrieved) |